vs
Apellis Pharmaceuticals, Inc.（APLS）与希尔威（SVM）财务数据对比。点击上方公司名可切换其他公司
希尔威的季度营收约是Apellis Pharmaceuticals, Inc.的1.1倍（$223.8M vs $199.9M），希尔威净利率更高（-1.3% vs -29.5%，领先28.2%），过去两年希尔威的营收复合增速更高（87.6% vs 7.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
希尔威金属矿业是一家总部位于加拿大、核心业务布局中国的贵金属企业，专注于含银矿产资源的收购、勘探与开发，在银矿资源运营领域具备成熟的产业经验。
APLS vs SVM — 直观对比
营收规模更大
SVM
是对方的1.1倍
$199.9M
净利率更高
SVM
高出28.2%
-29.5%
两年增速更快
SVM
近两年复合增速
7.7%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $223.8M |
| 净利润 | $-59.0M | $-2.9M |
| 毛利率 | — | — |
| 营业利润率 | -25.6% | — |
| 净利率 | -29.5% | -1.3% |
| 营收同比 | -5.9% | — |
| 净利润同比 | -62.2% | — |
| 每股收益（稀释后） | $-0.40 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSSVM
| Q4 25 | $199.9M | $223.8M | ||
| Q3 25 | $458.6M | — | ||
| Q2 25 | $178.5M | $72.2M | ||
| Q1 25 | $166.8M | — | ||
| Q4 24 | $212.5M | $172.5M | ||
| Q3 24 | $196.8M | $114.0M | ||
| Q2 24 | $199.7M | $60.0M | ||
| Q1 24 | $172.3M | — |
净利润APLSSVM
| Q4 25 | $-59.0M | $-2.9M | ||
| Q3 25 | $215.7M | — | ||
| Q2 25 | $-42.2M | $28.1M | ||
| Q1 25 | $-92.2M | — | ||
| Q4 24 | $-36.4M | $42.1M | ||
| Q3 24 | $-57.4M | $28.0M | ||
| Q2 24 | $-37.7M | $13.2M | ||
| Q1 24 | $-66.4M | — |
营业利润率APLSSVM
| Q4 25 | -25.6% | — | ||
| Q3 25 | 48.7% | — | ||
| Q2 25 | -18.6% | — | ||
| Q1 25 | -50.0% | — | ||
| Q4 24 | -12.3% | 30.5% | ||
| Q3 24 | -24.0% | 30.7% | ||
| Q2 24 | -14.7% | 30.0% | ||
| Q1 24 | -36.0% | — |
净利率APLSSVM
| Q4 25 | -29.5% | -1.3% | ||
| Q3 25 | 47.0% | — | ||
| Q2 25 | -23.6% | 39.0% | ||
| Q1 25 | -55.3% | — | ||
| Q4 24 | -17.1% | 24.4% | ||
| Q3 24 | -29.2% | 24.5% | ||
| Q2 24 | -18.9% | 22.0% | ||
| Q1 24 | -38.5% | — |
每股收益（稀释后）APLSSVM
| Q4 25 | $-0.40 | — | ||
| Q3 25 | $1.67 | — | ||
| Q2 25 | $-0.33 | — | ||
| Q1 25 | $-0.74 | — | ||
| Q4 24 | $-0.30 | — | ||
| Q3 24 | $-0.46 | — | ||
| Q2 24 | $-0.30 | — | ||
| Q1 24 | $-0.54 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | — |
| 总资产 | $1.1B | — |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSSVM
| Q4 25 | $466.2M | — | ||
| Q3 25 | $479.2M | — | ||
| Q2 25 | $370.0M | — | ||
| Q1 25 | $358.4M | — | ||
| Q4 24 | $411.3M | — | ||
| Q3 24 | $396.9M | — | ||
| Q2 24 | $360.1M | — | ||
| Q1 24 | $325.9M | — |
总债务APLSSVM
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | — |
股东权益APLSSVM
| Q4 25 | $370.1M | — | ||
| Q3 25 | $401.2M | — | ||
| Q2 25 | $156.3M | — | ||
| Q1 25 | $164.2M | — | ||
| Q4 24 | $228.5M | — | ||
| Q3 24 | $237.1M | — | ||
| Q2 24 | $264.3M | — | ||
| Q1 24 | $266.7M | — |
总资产APLSSVM
| Q4 25 | $1.1B | — | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $821.4M | — | ||
| Q1 25 | $807.3M | — | ||
| Q4 24 | $885.1M | — | ||
| Q3 24 | $901.9M | — | ||
| Q2 24 | $904.5M | — | ||
| Q1 24 | $831.9M | — |
负债/权益比APLSSVM
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $107.9M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | — |
| 自由现金流率自由现金流/营收 | -7.1% | — |
| 资本支出强度资本支出/营收 | 0.1% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | — |
8季度趋势，按日历期对齐
经营现金流APLSSVM
| Q4 25 | $-14.2M | $107.9M | ||
| Q3 25 | $108.5M | — | ||
| Q2 25 | $4.4M | $40.0M | ||
| Q1 25 | $-53.4M | — | ||
| Q4 24 | $19.4M | $81.3M | ||
| Q3 24 | $34.1M | $57.7M | ||
| Q2 24 | $-8.3M | $28.9M | ||
| Q1 24 | $-133.0M | — |
自由现金流APLSSVM
| Q4 25 | $-14.3M | — | ||
| Q3 25 | $108.3M | — | ||
| Q2 25 | $4.4M | — | ||
| Q1 25 | $-53.4M | — | ||
| Q4 24 | $19.3M | — | ||
| Q3 24 | — | $33.8M | ||
| Q2 24 | $-8.4M | $17.0M | ||
| Q1 24 | $-133.3M | — |
自由现金流率APLSSVM
| Q4 25 | -7.1% | — | ||
| Q3 25 | 23.6% | — | ||
| Q2 25 | 2.5% | — | ||
| Q1 25 | -32.0% | — | ||
| Q4 24 | 9.1% | — | ||
| Q3 24 | — | 29.6% | ||
| Q2 24 | -4.2% | 28.3% | ||
| Q1 24 | -77.3% | — |
资本支出强度APLSSVM
| Q4 25 | 0.1% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.0% | 21.0% | ||
| Q2 24 | 0.0% | 19.8% | ||
| Q1 24 | 0.2% | — |
现金转化率APLSSVM
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | — | 1.42× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 1.93× | ||
| Q3 24 | — | 2.06× | ||
| Q2 24 | — | 2.19× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
SVM
暂无分部数据
